nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And our agenda is rather modest. We need to tidy up around the castle, catch up on our napping, and plan to spend time with our short person. We may also promenade with the mascots. And what about you? Perhaps this is a good time to plan a spring break, reach out to someone special, or donate to the arts, which may need some help. Or you could check to see if you were wiretapped recently. But please do remember to gather evidence. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon …

AstraZeneca was dealt another setback by the Food and Drug Administration in its quest to win approval for a drug that treats hyperkalemia, a condition in which potassium levels in the blood are too high, the Financial Times says. The FDA issued a complete response letter, meaning the drug will not be approved. This is the second time the FDA declined to approve the drug, which AstraZeneca acquired when it bought ZS Pharma for $2.7 billion in 2015.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories